Physician profile
Douglas A Thomas
NPI 1730101023
$3,237.86
in general payments reported to CMS, 2019-2025
22 companies · $450 in 2025
The $450 reported for 2025 was less than what a typical Mohs-Micrographic Surgery provider received nationally (typical 2025 total: $462).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $767 · 2020: $146 · 2021: $308 · 2022: $810 · 2023: $304 · 2024: $452 · 2025: $450.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,164 · Education: $42.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,163.68 |
| Education | $42.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,012.05 | 2019-2025 | Skyrizi, Botox |
| Genzyme Corporation | $264.58 | 2019-2025 | |
| Regeneron Healthcare Solutions, INC. | $261.84 | 2019-2022 | |
| Pfizer INC. | $230.28 | 2019-2023 | |
| Novartis Pharmaceuticals Corporation | $165.93 | 2019-2021 | |
| Janssen Biotech, INC. | $161.74 | 2020-2025 | Tremfya, Stelara, Simponi |
| Ucb, INC. | $155.93 | 2022 | |
| Dermavant Sciences, INC. | $153.48 | 2023-2024 | Vtama |
| Sun Pharmaceutical Industries INC. | $132.98 | 2021-2025 | Ilumya, Absorica Ld, Winlevi |
| Lilly USA, LLC | $132.48 | 2022-2024 | Ebglyss |
| Aclaris Therapeutics, INC. | $118.74 | 2019 | |
| Strata Skin Sciences, INC. | $75.00 | 2019 | |
| Amgen INC. | $68.74 | 2020-2021 | |
| Stemline Therapeutics INC. | $57.11 | 2021 | |
| Almirall LLC | $56.45 | 2019-2022 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Incyte Corporation | $50.30 | 2022 | |
| Arcutis Biotherapeutics, INC. | $36.43 | 2024-2025 | Zoryve |
| Dermira, INC. | $32.67 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $24.45 | 2024 | |
| Leo Pharma INC. | $19.61 | 2023 | Adbry |
| Genentech USA, INC. | $14.98 | 2019 | |
| Galderma Laboratories, L.P. | $12.09 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Douglas Thomas listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.